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Abstract
Purpose: Positive results of phase I studies evaluating lenvati-
nib in solid tumors, including thyroid cancer, prompted a phase II
trial in advanced medullary thyroid carcinoma (MTC).
Experimental Design: Fifty-nine patients with unresectable
progressive MTC per Response Evaluation Criteria In Solid
Tumors (RECIST) v1.0 within the prior 12 months received
lenvatinib (24-mg daily, 28-day cycles) until disease progression,
unmanageable toxicity, withdrawal, or death. Prior anti-VEGFR
therapy was permitted. The primary endpoint was objective
response rate (ORR) by RECIST v1.0 and independent imaging
review.
Results: Lenvatinib ORR was 36% [95% conﬁdence interval
(CI), 24%–49%]; all partial responses. ORR was comparable
between patients with (35%) or without (36%) prior anti-VEGFR
therapy. Disease control rate (DCR) was 80% (95% CI, 67%–
89%); 44% had stable disease. Among responders, median time
to response (TTR) was 3.5 months (95% CI, 1.9–3.7). Median
progression-free survival (PFS) was 9.0 months (95%CI, 7.0–not
evaluable). Common toxicity criteria grade 3/4 treatment-emer-
gent adverse events included diarrhea (14%), hypertension (7%),
decreased appetite (7%), fatigue, dysphagia, and increased ala-
nine aminotransferase levels (5% each). Ret proto-oncogene
status did not correlate with outcomes. Low baseline levels of
angiopoietin-2, hepatocyte growth factor, and IL8were associated
with tumor reduction and prolonged PFS. High baseline levels of
VEGF, soluble VEGFR3, and platelet-derived growth factor BB,
and low baseline levels of soluble Tie-2, were associated with
tumor reduction.
Conclusions: Lenvatinib had a high ORR, high DCR, and a
short TTR in patients with documented progressive MTC. Toxi-
cities were managed with dose modiﬁcations and medications.
Clin Cancer Res; 22(1); 44–53. 2015 AACR.
Introduction
Medullary thyroid carcinoma (MTC) is a rare neuroendo-
crine tumor arising from the parafollicular C cells in the
thyroid gland. MTC accounts for about 4% of all thyroid
cancers (1), whereas differentiated thyroid cancer (DTC), a
tumor of epithelial origin, accounts for more than 90% (2).
The overall 10-year survival rate of patients with MTC ranges
from 96% for patients with intrathyroid disease to 40%
for patients with locally advanced disease or with distant
metastases (3). Total thyroidectomy and neck lymph node
dissection is considered the most effective therapeutic
approach (1, 4, 5), although patients with distant metastases
may not fully beneﬁt from extensive surgery (3). For these
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patients with advanced disease, surgery is considered pallia-
tive and radiotherapy or chemotherapy is generally poorly
effective (6).
Approximately 75%ofMTC cases present in sporadic form and
the remainder in a hereditary pattern (7, 8). Germline mutations
in the RET proto-oncogene (RET; rearranged during transfection)
occur in nearly all cases of hereditary MTC (9). Somatic RET
mutations occur in approximately 40%of sporadicMTCcases and
have been associated with aggressive disease and poor prognosis
(10). In addition, RASmutations may play a role in RET-negative
MTC tumorigenesis (11). Aberrant RET- or RAS-mediated activa-
tion of signaling cascades (including theMAPK and phosphatidyl
4,5 bisphosphonate-3 kinase/alpha serine/threonine protein
kinase pathways) is considered the major pathogenic event of
MTC (12, 13).
MTC tumors are highly vascularized, with angiogenesis
mediated principally by VEGFRs but also FGF and platelet-
derived growth factor (PDGF) and their receptors (14). Over-
expression of VEGF and VEGFR2 has been observed in 50% to
95% of MTC tumors and is associated with metastases (15–17).
Currently, two multitargeted tyrosine kinase inhibitors (TKI)—
vandetanib and cabozantinib, each with activity against RET
and VEGFR2—have been approved by the FDA and the Euro-
pean Medicines Agency for treatment of locally advanced or
metastatic MTC on the basis of results from phase III trials
demonstrating improved progression-free survival (PFS) over
placebo (18, 19).
Lenvatinib is an oral, multitargeted TKI that inhibits VEGFR 1–
3, FGFR 1–4, PDGFRa, RET, and v-kit Hardy–Zuckerman 4 feline
sarcoma viral oncogene homolog (KIT; refs. 20–23) that has
recently been approved for the treatment of radioiodine-refrac-
toryDTC (RR-DTC)on thebasis of the results of the SELECTphase
III trial (24). Preclinical and phase I evidence of antitumor efﬁcacy
in a variety of solid tumor types, including thyroid cancer (25–
28), prompted the initiation of a phase II trial in advanced,
unresectable progressiveMTC andRR-DTC, stratiﬁed by histology
(29). Here, we present results from the MTC component of the
study.
Materials and Methods
Study design and treatment
This was a phase II, multicenter, open-label, single-arm clinical
trial in patients with MTC and RR-DTC (Clinicaltrials.gov Trial
Registration ID: NCT00784303). These are two distinct diseases
with different prognoses; therefore, the study was designed with
distinct entry criteria for eachdisease and to analyze and report the
outcomes separately. The study was conducted at 30 sites in the
United States, United Kingdom, Australia, France, Italy, and
Poland, approved by the Institutional Review Board or Ethics
Committee at eachparticipating site and carried out in accordance
with the Declaration of Helsinki. All patients provided written
informed consent. Treatment consisted of once-daily oral lenva-
tinib administered at a starting dose of 24mg in 28-day treatment
cycles for 8 cycles in the absence of disease progression, unman-
ageable toxicities, withdrawal, or death. Dose reductions occurred
for grade 2 adverse events (AE) except for hypertension, nausea,
and vomiting, which were ﬁrst managed by medical treatment.
Once the dose was reduced, it could not be increased.
Patients
Patients were 18 years of age with unresectable or metastatic
histologically or cytologically conﬁrmed MTC with at least one
measurable lesion by Response Evaluation Criteria In Solid
Tumors version 1.0 (RECIST v1.0; ref. 30) and either computed
tomography (CT) or MRI scans. Patients also had documented
disease progression within 12 months prior to study entry (as
assessed by the investigator with CT or MRI scans per RECIST).
Prior chemotherapy and anti-VEGFR treatments were allowed but
must have been discontinued at least 30 days prior to study entry.
Patients with signiﬁcant cardiac, hematopoietic, hepatic, or renal
dysfunction; metastases to the brain or leptomeningeal metasta-
ses; or use of anticoagulants were excluded.
Tumor response
The primary endpoint was objective response rate (ORR), per
RECIST v1.0 criteria as assessed by independent imaging review
(IIR). Secondary endpoints included PFS, overall survival (OS),
disease control rate [DCR; deﬁned as complete response (CR),
partial response (PR), or stable disease (SD)], time to response
(TTR) based on IIR, duration of response, and safety and toler-
ability. SDwas deﬁned as stable disease lasting7weeks; durable
SD was deﬁned as SD for 23 weeks.
Patient monitoring and tumor assessment
Physical examinations and laboratory evaluations were con-
ducted on days 1, 8, 15, and 22 of cycle 1; on day 1 of cycle 2; and
then on day 1 of every 28-day cycle. Investigators were permitted
to continue lenvatinib treatment until documented disease pro-
gression or unacceptable toxicity.
Within 4 weeks prior to initiation of treatment, tumor assess-
ments using CT of the neck/chest/pelvis and MRI or CT of the
abdomen were performed and assessed as the baseline tumor
burden. Follow-up assessments in accordance with RECIST v1.0
were performed every other cycle or sooner if there was suspicion
of progressive disease (PD). Tumor response was evaluated at the
site, and if PRorCRwas reported, the responsewas veriﬁed at least
4weeks afterﬁrst observed. The IIRof tumor responsewasused for
the primary and secondary efﬁcacy assessments. Designation of
SD for best overall response (BOR) required at least one post-
treatment assessment of SD at aminimumof 7weeks after theﬁrst
Translational Relevance
Lenvatinib, an oral, multitargeted tyrosine kinase inhib-
itor of the VEGFR1–3, FGFR1–4, PDGFRa, RET, and KIT
signaling networks, demonstrated antitumor activity in
phase I studies against several solid tumors, including in
advanced medullary thyroid cancer (MTC). This phase II
study demonstrated an objective response rate (ORR) for
lenvatinib of 36% in patients with progressive MTC. The
ORR was similar between patients with (35%) and without
prior anti-VEGF therapy (36%). Treatment with lenvatinib
was associated with a well-deﬁned safety proﬁle that was
managed with dose modiﬁcations and medications. This
study also explored potential biomarkers that may be indic-
ative of a response to lenvatinib, with lower baseline levels
of angiopoietin-2 associated with greater tumor reduction
and prolonged progression-free survival. These ﬁndings
support the continued investigation of lenvatinib for the
management of advanced MTC.
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dose. At baseline [cycle 1 day 1 (C1D1)] and every 4 cycles, bone
scans were performed.
Archival tumor tissues were available and obtained from 24 of
59 patients. Exploratory correlative analyses of tumor genetics,
serum levels of 51 circulating cytokine and angiogenic factors
(CAF), calcitonin (Ct), and carcinoembryonic antigen (CEA)with
tumor responses to lenvatinib treatment were conducted. A total
of 32 genes and 443mutationswere assessed using the Sequenom
Mass ARRAY iPLEX OncoCarta v1.0 and v3.0 Platform (Seque-
nom, Inc.). A panel of 51 CAFs was assayed using ELISA and
multiplex assays. Sample data acquisition and analysis were
performed on either an ELISA plate reader using SoftmaxPro
software (Molecular Devices) or the BioRad Bio-Plex System
(Bio-Rad Laboratories) using Bio-Plex Manager 4.1 software for
multiplex assays. CAFs for which >20% of patients had out-of-
range measurements were not included in correlative analyses. Ct
and CEA measurements were performed using chemilumines-
cence immunoassays on Immulite 2000 and Centaur instru-
ments, respectively.
Statistical analysis
Sample size estimates were calculated on the basis of Simon
optimal 2-stage design, assuming an expected ORR of 15% with
lenvatinib compared with 2.5% based on historical controls, at
90%power and a of 0.5. In this two-stage design, 16 patients were
required in stage 1; if at least 1 conﬁrmed CR or PR was observed
by IIR, the study would continue to stage 2 to enroll a total of 52
patients. Otherwise, enrollment would be stopped for futility.
However, because of rapid enrollment, all subjects were enrolled
before the scheduled interim analysis (when the 16th evaluable
patient completed 6 treatment cycles); nevertheless, becausemore
than one conﬁrmed responder was observed among the ﬁrst 16
patients prior to the enrollment of additional patients, the crite-
rion for moving to the second stage was already met. All patients
received at least one lenvatinib dose and had at least one post-
treatment safety assessment and were therefore included in both
the intent-to-treat (ITT) and safety populations. The ITT popula-
tion was used for the primary efﬁcacy analyses. For the primary
efﬁcacy endpoint, ORRwas calculated at the time of data cut off—
either when all treated patients completed 8 cycles or discon-
tinued treatment prior to the eighth cycle. Two-sided 95% con-
ﬁdence intervals (CI) for the ORR were calculated using Clopper
and Pearson method. Descriptive statistics were used to summa-
rize patient demographic data and safety parameters. PFS, esti-
mation of PFS at 6 and 12 months, OS, and duration of response
(for responders) were calculated using Kaplan–Meier product–
limit estimates.
Mutation analyses were designed to test relationships
between tumor mutation status and maximum change in
tumor size, ORR, and PFS; for these analyses, the Mann–
Whitney test, Fisher exact test, and log-rank test were applied,
respectively. Posttreatment serum biomarker fold changes from
baseline were analyzed by the Wilcoxon signed-rank test. Log-
transformed values were used to test for associations between
tumor responses and CAF levels. Circulating CAF levels were
evaluated against maximum change in tumor size and PFS; for
these analyses, the Spearman rank correlation test and the Cox
proportional hazard model with Wald test P values were
applied, respectively. Kaplan–Meier curves for high and low
CAF level groups using a median cutoff were drawn. To test for
Ct or CEA changes and their associations with tumor shrinkage
and PFS, the Spearman rank correlation test and univariate Cox
proportional hazard models with Wald test P values were
applied, respectively. Unadjusted P values and false discovery
rates (FDR) for multiple comparisons are reported for the
biomarker analyses. Results with P < 0.05 were reported.
Statistical analyses were performed using R version 2.15.0 or
later (R Foundation for Statistical Computing) with the fol-
lowing packages: survival and doMC (parallel computation).
Results
Patient demographics and baseline characteristics
Between October 2008 and August 2010, 162 patients with
either DTC or MTC were screened and 117 were treated. For the
MTC population (n ¼ 59), the mean age was 52 years and the
majority were male (63%), White (93%), had baseline Eastern
Cooperative Oncology Group (ECOG) scores of  1 (97%), and
New York Heart Association (NYHA) classiﬁcation of 1
(85%; Table 1). Furthermore, 44%had received prior anti-VEGFR
therapy, 49% had received radiotherapy and 15% had received
conventional chemotherapy. The most common sites of metas-
tases were liver (68%), mediastinum (58%), lung (53%), and
bone (44%). Sixteen of the 24 analyzed patient tumors (67%)
were RET mutant–positive (RETM918T: n ¼ 14; RETC634R: n ¼ 2).
Patient disposition
Thirty (51%) patients discontinued treatment for the following
primary reasons: disease progression (25%), AE (22%), and
patient choice (3%).
Tumor response
After a minimum 8 months of follow-up, the ORR as assessed
by IIR was 36% (95% CI, 24%–49%), with only PRs reported
(Table 2). No obvious differences in ORR by age, gender, or prior
anti-VEGFR therapy were observed. A BOR of SD was observed in
44% of patients and durable SD in 29% of patients. The DCRwas
80% (95% CI, 67%–89%). For patients who responded to treat-
ment, themedian TTRwas 3.5months (95%CI, 1.9–3.7), and the
median duration of response based on IIR assessments was not
reached because of the high proportion of censored patients. A
waterfall plot of the maximum tumor percentage change from
baseline topostbaseline nadir is shown inFig. 1A. ThemedianPFS
as assessed by IIR was 9.0 months [95% CI, 7.0–not evaluable
(NE); Fig. 1B]. The 6-month PFS rate was 67% (95% CI, 52%–
78%) and the 12-month PFS rate was 46% (95% CI, 31%–60%).
The overall median OS was 16.6 months (95% CI, 16.4–NE;
Supplementary Fig. S1).
Tumor response based on prior anti-VEGFR therapy
Tumor responseswere similar regardless of prior history of anti-
VEGFR therapy. TheORR for patients who did (n¼ 26) or did not
(n ¼ 33) receive prior VEGFR therapy was 35% (95% CI, 17%–
56%) and 36% (95% CI, 20%–55%), respectively (all PRs). The
median duration of response for patients who had received prior
VEGFR treatment and responded to lenvatinib therapy (n ¼ 9)
was 5.7 months (95% CI, 4.5–NE) and was not reached for
lenvatinib responders without prior VEGFR treatment (n ¼
12). The median PFS was 7.3 months (95% CI, 4.0–NE) in
patients with prior VEGFR therapy and 12.9 months (95% CI,
7.1–NE) for patients without prior VEGFR therapy. The median
OS for patients with prior VEGF-targeted therapy was also
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16.6 months (95% CI, NE–NE), whereas median OS for patients
without prior therapy was not reached at data cutoff.
Pharmacogenomic and pharmacodynamics analyses
An examination of genetic alterations in 24 archival patient
tumor tissues yielded a total of 11 different mutations in 7 genes
from 18 patient tumors. Of note, RET tumor mutation status did
not show a statistically signiﬁcant association with tumor shrink-
age (P ¼ 0.920), ORR (P ¼ 1.000), or PFS (P ¼ 0.313). An NRAS
mutant–positive patient achieved SD and 2 patients with dual
PIK3CA and RETM918T mutations had PRs.
After 8 days of treatment with lenvatinib, changes were
observed in the levels of 13 of the 51 testedCAFs (Fig. 2). Notably,
thereweredecreases in levels of 6CAFs, including solubleVEGFR2
(sVEGFR2), sVEGFR3, and angiopoietin-2, and increases in levels
of 7 CAFs: IFNg-induced protein (IP)-10, VEGF, and stromal cell–
derived factor (SDF)-1a. Low baseline levels of angiopoeitin-2,
Tie-2, hepatocyte growth factor (HGF), and IL8 and high baseline
levels of VEGF, sVEGFR3, and the homodimer of PDGF-beta
polypeptide (PDGF-BB) were associated with greater tumor
shrinkage (Fig. 3A). Low baseline levels of angiopoietin-2, HGF,
and IL8 were associated with prolonged PFS (Fig. 3B).
Serum Ct and CEA levels decreased upon lenvatinib treatment
in almost all patients [Ct decreased by amedian 0.49-fold by cycle
2 day 1 (C2D1) in 47 of 52 patients; CEA decreased by a median
0.60-fold by cycle 3 day 1 (C3D1) in 44 of 50 patients]. These
changes were signiﬁcantly correlated with ORR and prolonged
PFS, respectively (C2D1 Ct, P ¼ 0.012 and P ¼ 0.001; HR, 1.72;
95% CI, 1.25–2.38; C3D1 CEA, P ¼ 0.032 and P ¼ 0.003, HR,
2.06; 95% CI, 1.28–3.32). When adjusted for multiple compar-
isons, these associations were no longer signiﬁcant (C2D1 Ct,
FDR P ¼ 0.311 for ORR and FDR P ¼ 0.086 for PFS; C3D1 CEA,
FDR P ¼ 0.327 for ORR and FDR P ¼ 0.114 for PFS).
Treatment duration, safety, and tolerability
All patients experienced treatment-emergent AEs (TEAE). The
most common TEAEs were diarrhea (75%), proteinuria (59%),
fatigue (53%), hypertension (51%), decreased appetite (49%),
nausea (48%), decreased weight (42%), headache (41%), vomit-
ing (37%), and cough (36%; Table 3). Most hypertension and
proteinuria events were grade 1 or 2 and managed with standard
medical interventions. Themedian duration of treatmentwas 264
days (range, 13–547 days). At least 8 cycles of lenvatinib treat-
mentwere received by64%of patients, with ameandose intensity
of 19.1 mg/d. Dose reduction, interruption, or treatment with-
drawal due to TEAEs was required in 59%, 75%, and 24% of
patients, respectively.Dose reductions to20, 14, 10, and8mg/dof
lenvatinib occurred in 56%, 39%, 8%, and 2% of patients,
respectively. The median time to the ﬁrst dose reduction was
2.2 months (range, 0.5–16.6). TEAEs that led to lenvatinib
withdrawal andoccurred inmore thanone patientwere decreased
appetite and decreased weight (3% each). Withdrawal from
treatment due to hypertension occurred in one patient (2%).
Skin-related TEAEs included palmar–plantar erythrodysesthe-
sia syndrome (24%), rash (22%), dry skin (17%), alopecia and
hyperkeratosis (12% each), and skin exfoliation (10%). One
patient (2%) experienced grade 1 folliculitis. Two patients
(3%) experienced grade 3 palmar–plantar erythrodysesthesia
syndrome and one patient (2%) experienced grade 4 exfoliative
rash. The grade 4 exfoliative rash lasted for 8 days andwas deemed
unrelated to study treatment by the investigator; the study dose
was therefore not changed, and the patient recovered.
Table 1. Patient demographics and baseline characteristics (ITT population)
Category Patients (N ¼ 59)
Mean age at study entry, y (min, max) 51.6 (22, 74)
Sex, n (%)
Male 37 (63)
Female 22 (37)
Race/ethnicity, n (%)
White 55 (93)
African American 1 (2)
Other 3 (5)
NYHA classiﬁcation, n (%)
1 50 (85)
2 7 (12)
3 or 4 0
Unknown 2 (3)
ECOG performance status, n (%)
0 32 (54)
1 25 (42)
2 2 (3)
Patients with positive RET mutation
status, n (%)
16/24a (67)
Number of previous anticancer therapy
regimens, n (%)
0 25 (42)
1 22 (37)
2 5 (9)
3 7 (12)
Patients with previous conventional
chemotherapy, n (%)
9 (15)
Patients with previous radiotherapy, n (%) 29 (49)
Patients with previous anti-VEGF therapy, n (%) 26 (44)
Cabozantinib 11 (19)
Sorafenib 6 (10)
Vandetanib 4 (7)
Motesanib 3 (5)
Sunitinib 3 (5)
Other 3 (5)
Sites of metastasis at baselineb
Liver 38 (64)
Bone 19 (32)
Lung 9 (15)
Symptoms at baseline
Diarrhea 31 (53)
Musculoskeletal pain 26 (44)
a24 Patients were evaluated for RET mutation status.
bOn the basis of study entry screening.
Table 2. Tumor responses based on IIR assessments (ITT population)
Parameter, n (%) Overall (N ¼ 59)
ORR (CR þ PR) 21 (36)
95% CI 24–49
Best overall tumor responsea
CR 0
PR 21 (36)
SD (7 wks) 26 (44)
Durable SD(23 wks) 17 (29)
PD 7 (12)
NE 2 (3)
Unknown 3 (5)
DCR (CR þ PR þ SD) 47 (80)
95% CI 67, 89
TTR, mo, median (95% CI) 3.5 (1.9–3.7)
Duration of response, mo, median (95% CI) NE (5.7–NE)
aResponses were evaluated on the basis of the modiﬁed RECIST criteria.
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Common Toxicity Criteria (CTC) grade 3 TEAEs occurred in 36
patients (61%). Grade 3 TEAEs that occurred in at least 5% of
patients included diarrhea (14%), hypertension (7%), decreased
appetite (7%), fatigue (5%), dysphagia (5%), and increased levels
of alanine aminotransferase (5%). There were 5 grade 4 TEAEs
that occurred in one patient each: increased levels of amylase,
increased levels of lipase, exfoliative rash, accidental narcotic
overdose, and pneumonia aspiration.
Serious AEs (SAE) occurred in 51% of patients and those that
occurred in at least two patients included decreased appetite
(5%), pulmonary embolism, abdominal pain, pneumonia, lung
infection, dehydration, and premature menopause (3.4% each).
SAEs led to dose interruption in 15.3%, dose reduction in 8.5%,
and study drug withdrawal in 8.5% of patients. Four deaths
occurred during treatment or within 30 days of the last lenva-
tinib dose. Of these, one death was due to clinical PD and 3
were due to AEs, including respiratory arrest (not otherwise
speciﬁed), respiratory failure, and paraneoplastic syndrome—
with only the death by respiratory failure deemed treatment-
related by the treating physician. An additional death occurred
in a patient with tracheal–esophageal ﬁstula that was study
treatment–related; this event was recorded as an SAE, but not as
a fatal AE.
Discussion
Distant metastases are the main cause of death in patients with
advancedMTCwith little evidence supporting the use of cytotoxic
chemotherapy in these patients (14). Increased understanding of
molecular mechanisms implicated in the pathogenesis and pro-
gression of MTC has prompted development of TKIs with activity
against critical mediators of the relevant signaling pathways
involved, including RET and VEGFR (6).
We evaluated oral lenvatinib (24 mg administered once-daily)
for the treatment of unresectable or metastatic MTC and RECIST
v1.0–documented disease progression at baseline in 59 patients,
of which almost half of all patients had received prior anti-VEGFR
treatment or had bone metastases. A conﬁrmed ORR was
observed in 36% of patients with only PRs reported. The median
PFS was 9 months and the estimated PFS rate at 6 months was
67%. In this study, although there was a numerical difference in
median PFS between patients with and without prior VEGF-
targeted therapy, tumor response was similar in both groups,
conﬁrming the lack of cross-resistance between TKIs previously
suggested in a study of cabozantinib therapy in patientswith prior
VEGFR-targeted treatment (19).
Although results across different clinical trials are difﬁcult to
interpret, the tumor responses observed for lenvatinib in this
trial are encouraging in the context of what has been reported
for other TKIs. A phase II trial of vandetanib in patients with
locally advanced or metastatic hereditary MTC showed a con-
ﬁrmed/unconﬁrmed PR rate of 30% (31), and the subsequent
phase III trial reported a 45% ORR in vandetanib-treated MTC
patients, with a 6-month PFS rate of 83% (18). However, PD
was not required to be present at study entry in either of these
vandetanib trials, and the phase II trial was limited to patients
with hereditary disease, both of which could have inﬂuenced
the observed tumor response. Of note, a median PFS of 19
months was observed for placebo patients in the ZETA trial. In
contrast, a phase III study of cabozantinib in unresectable
locally advanced or metastatic MTC did require evidence of
disease progression within 14 months of screening (19).
Results showed statistically signiﬁcant advantages in favor of
cabozantinib over placebo in ORR (28% vs. 0%) and the
median PFS was 11.2 months in the cabozantinib arm and 4
months in the placebo arm. Therefore, despite the approval of
both vandetanib and cabozantinib for the treatment of MTC,
there is clearly still a need for effective TKI treatments in
patients with progressive MTC.
Lenvatinib at the starting dose of 24mgonce daily has a toxicity
proﬁle characterized by predominantly CTC grade  2 TEAEs,
including diarrhea, proteinuria, hypertension, fatigue, decreased
appetite, nausea, decreased weight, vomiting, and abdominal
pain. Twenty-two percent of patients withdrew from the study
due to TEAEs. TheAEproﬁle of lenvatinibwas generally consistent
with anti-VEGFR treatment of advanced MTC (14). Most hyper-
tension and proteinuria events were grade  2 and most TEAEs
were managed with standard medical care and dose interruption
Figure 1.
A, waterfall plot of percent change in summed longest diameter of target
lesions from baseline by independent imaging review of the efﬁcacy
evaluable subjects per protocol (n¼50). No tumor changedatawere available
for 3 patients with "Unknown" as their BOR. B, PFS by independent imaging
review of the ITT population.  , patients previously treated with an anti-
VEGFR therapy; †, although this patient had tumor shrinkage in the target
lesion, the BOR of the patient was considered SD, as a baseline nontarget
lesion became nonevaluable at a later assessment.
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or reduction when necessary. A high incidence of diarrhea was
seen, although diarrhea is often also a complication of MTC. CTC
grade 3 or 4 TEAEs, most of which were of grade 3 severity, were
experienced by 70%of patients, most commonly diarrhea (12%),
hypertension (7%), and decreased appetite (7%). Fifty-one per-
cent of patients had SAEs.
Of interest in this studywas the generally low incidence of grade
3 skin toxicities. The incidence of palmar–plantar erythrody-
sesthesia syndrome (also known as hand–foot syndrome), was
24%; grade 3 palmar–plantar erythrodysesthesia syndrome
occurred in 3.4% of patients. The incidence of rash was 22% and
one grade 4 exfoliative rash event occurred. In a phase II trial of
sorafenib for metastatic MTC, the incidence of palmar–plantar
erythrodysesthesia syndrome was 76% with grade 3 events
occurring in 14% of patients (32). In the same trial, the incidence
of rash was 67% with no grade 3 rash events. In the ZETA trial,
45% of vandetanib-treated patients experienced rash and 4%
experienced grade  3 rash events (18). In the present study,
only one patient experienced grade 1 folliculitis. Folliculitis has
been noted as a common AE identiﬁed in clinical studies with
patients receiving vandetanib as treatment for MTC (33). There-
fore, the use of lenvatinib may be associated with fewer skin
toxicities, but this would need conﬁrmation in placebo-con-
trolled trials.
In this exploratory biomarker study of a limited number of
patients, tumor response did not appear to correlate with RET
mutation status. In addition, although RAS mutations are the
second most important driver mutation in MTC, only a single
NRAS-mutant tumor was identiﬁed in this study, possibly due to
the limited number of tumors analyzed, as well as the method of
genetic testing,which limited the range ofmutations that could be
identiﬁed. The associations found between changes in CAF levels
Figure 2.
Change in serum CAF levels during lenvatinib
treatment. a, by ELISA; b, by multiplex array.
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and clinical outcomes of lenvatinib treatment suggest that anti-
angiogenic activity contributed to the observed antitumor activity
in this study. This is consistent with results of a phase I clinical
trial inmetastaticMTC that showed that exposure to cabozantinib
resulted in signiﬁcant changes in the levels of placental growth
factor, VEGF-A, and VEGFR2 (34). Correspondingly, the present
study detected changes in the levels of sVEGFR2, sVEGFR3, and
VEGF-A in patient serum, as well as changes in levels of angio-
poietin-2, sTie-2, SDF-1a, and IP-10 after 8 days of lenvatinib
treatment.
We also observed that low baseline levels of angiopoietin-2,
sTie-2, HGF, and IL8 were associated with greater tumor shrink-
age; angiopoietin-2, HGF, and IL8 were additionally associated
with prolonged PFS. HGF and IL8 are factors known to be
Figure 3.
Correlation of baseline cytokine and angiogenic factor levelswith clinical outcome. A, correlation of baseline cytokine and angiogenic factor levelswithmaximum tumor
shrinkage. B, Kaplan–Meier plots of PFS stratiﬁed by high and low baseline cytokine and angiogenic factor levels (median cutoff). (Continued on the following page.)
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associated with resistance to anti-VEGF therapy (35, 36). Our
results suggest that angiopoietin-2/Tie-2 signaling may also con-
tribute to VEGFor TKI treatment resistance (37); however,most of
these markers lose statistical signiﬁcance after adjustment for
multiple analyses. Therefore, further study is needed to validate
these proposed angiogenic biomarkers in appropriately powered
and controlled clinical trials.
In conclusion, oral lenvatinib, dosed once daily at 24 mg, was
associated with anORR of 36%, short TTR, prolonged duration of
response, and a 6-month PFS rate of 67%. The observed toxicity
proﬁle was consistent with anti-VEGF treatment but with poten-
tially greater incidence of weight loss and less clinically bother-
some dermatological TEAEs. These results suggest that lenvatinib
provides clinically meaningful tumor control with toxicities that
were managed by symptomatic treatments and dose modiﬁca-
tions in this pretreated population of patients.
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Event,
n (%)
All grades
(N ¼ 59)
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(N ¼ 59)
Diarrhea 44 (75) 8 (14)
Proteinuria 35 (59) 1 (2)
Fatigue 31 (53) 3 (5)
Hypertension 30 (51) 4 (7)
Decreased appetite 29 (49) 4 (7)
Nausea 28 (48) 1 (2)
Decreased weight 25 (42) 2 (3)
Headache 24 (41) 1 (2)
Vomiting 22 (37) 0
Cough 21 (36) 0
Dysphonia 19 (32) 0
Arthralgia 17 (29) 1 (2)
Dyspnea 16 (27) 1 (2)
Abdominal pain upper 15 (25) 1 (2)
Abdominal pain 15 (25) 1 (2)
Pain in extremity 15 (25) 2 (3)
Constipation 14 (24) 1 (2)
Palmar–plantar erythrodysesthesia
syndrome
14 (24) 2 (3)
Musculoskeletal pain 13 (22) 0
Rash 13 (22) 0
Blood thyroid-stimulating
hormone level increased
12 (20) 0
Glossodynia 12 (20) 0
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Stomatitis 12 (20) 0
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